|
| Primary information |
|---|
| ID | 10144 |
| Therapeutic ID | Th1020 |
| Protein Name | Asparaginase |
| Sequence | >Th1020_Asparaginase
MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
|
| Molecular Weight | 31731.9 |
| Chemical Formula | C1377H2208N382O442S17 |
| Isoelectric Point | 4.67 |
| Hydrophobicity | 0.059 |
| Melting point | NA |
| Half-life | 8-30 hours |
| Description | L-asparagine amidohydrolase from E. coli |
| Indication/Disease | To treat acute lympocytic leukemia and non-Hodgkins lymphoma |
| Pharmacodynamics | In most patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells. |
| Mechanism of Action | Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxalo-acetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and thus the loss of exogenous sources of asparagine leads to cell death. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Apparent volume of distribution was slightly greater than the plasma volume. Asparaginase levels in cerebrospinal fluid were less than 1% of concurrent plasma levels |
| Clearance | NA |
| Categories | Amidohydrolases, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Asparaginase, Asparagine-specific Enzyme, Enzymes, Enzymes and Coenzymes, Hydrolases, Narrow Therapeutic Index Drugs, Thyroxine-binding globulin inhibitors |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | Rylaze, Spectrila |
| Company | Jazz Pharmaceuticals, Inc., Medac Gesellschaft Fuer Klinische Spezialpraeparate Mb H |
| Brand Description | Jazz Pharmaceuticals, Inc., Medac Gesellschaft Fuer Klinische Spezialpraeparate Mb H |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | Central neurotoxicity: excessive sleepiness, depression, hallucinations, agitation, disorientation or seizure, stupor, confusion and/or coma. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |